---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-030020"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:32:24.016284+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4DMT reports FY2024 net loss of $160.9M; cash $505M; Phase 3 programs on track

## Summary
- Net loss of $160.9M in 2024 vs $100.8M in 2023; R&D expenses $141.3M (up 46% YoY).
- Cash, cash equivalents and marketable securities of $505M as of Dec 31, 2024, funding operations into 2028.
- Phase 3 4FRONT trials for 4D-150 in wet AMD to initiate March 2025 and Q3 2025; topline data expected H2 2027.
- FDA aligned that a single Phase 3 trial is acceptable for BLA submission of 4D-150 in DME.
- Pipeline focused on 4D-150 (wet AMD, DME) and 4D-710 (CF); paused other programs and terminated early-stage rare disease trials.

## SEC filing metadata
- accession: 0000950170-25-030020
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/0000950170-25-030020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/fdmt-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-030020
- JSON: https://secwatch.observer/filing/0000950170-25-030020.json
- Plain text: https://secwatch.observer/filing/0000950170-25-030020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.